Abstract
The updated 2016 WHO classification of hematopoietic tumors has a new category: “myeloid neoplasms with germline predisposition.” These entities are rare, but are also currently underdiagnosed and underreported. Recognition is critical for appropriate clinical evaluation and therapy, with potential implications for the patient’s entire family. The WHO includes 3 categories of myeloid neoplasms with germline predisposition: neoplasms without preexisting conditions, neoplasms with a history of thrombocytopenia, and neoplasms with other organ dysfunction. Specialized molecular testing is frequently necessary to make the diagnosis, as the presence of one of the implicated mutations is not sufficient for diagnosis and should be confirmed with germline DNA evaluation. Many families have unique mutations that are not detected by targeted sequencing panels. Periodic bone marrow (BM) examinations are recommended to assess patients’ baseline morphology and rule out evidence of disease progression. Thus, accurate diagnosis requires a careful recording of clinical history, a BM morphology evaluation, and advanced molecular testing.
Journal Section:
Editor's choice
References
1.
Czuchlewski DR, Peterson LC: myeloid neoplasms with germline predisposition: a new provisional entity within the World Health Organization classification. Surg Pathol Clin 2016; 9: 165–76.
2.
University of Chicago Hematopoietic Malignancies Cancer Risk Team: How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 2016; 128: 1800–1813.
3.
West AH, Godley LA, Churpek JE: Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann NY Acad Sci 2014; 1310: 111–118.
4.
Bacher U, Kohlmann A, Haferlach T: Mutational profiling in patients with MDS: ready for every-day use in the clinic? Best Pract Res Clin Haematol 2015; 28: 32–42.
5.
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J: Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004; 351: 2403–2407.
6.
Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU: Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008; 26: 5088–5093.
7.
Tawana K, Wang J, Renneville A, et al: Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 2015; 126: 1214–1223.
8.
Polprasert C, Schulze I, Sekeres MA, et al: Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015; 27: 658–670.
9.
Cardoso SR, Ryan G, Walne AJ, et al: Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia 2016; 30: 2083–2086.
10.
Lewinsohn M, Brown AL, Weinel LM, et al: Novel germline DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood 2016; 127: 1017–1023.
11.
Li R, Sobreira N, Witmer PD, Pratz KW, Braunstein EM: Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 2016; 101:e228–e231.
12.
Song WJ, Sullivan MG, Legare RD, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166–175.
13.
Bluteau D, Glembotsky AC, Raimbault A, et al: Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood 2012; 120: 2708–2718.
14.
Kirito K, Sakoe K, Shinoda D, Takiyama Y, Kaushansky K, Komatsu N: A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Haematologica 2008; 93: 155–156.
15.
Latger-Cannard V, Philippe C, Bouquet A, et al: Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French Network on Inherited Platelet Disorders. Orphanet J Rare Dis 2016; 11: 49.
16.
Glembotsky AC, Bluteau D, Espasandin YR, et al: Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets. J Thromb Haemost 2014; 12: 761–772.
17.
Kanagal-Shamanna R, Loghavi S, DiNardo CD, et al: Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 2017; 102: 1661–1670.
18.
Tsang HC, Bussel JB, Mathew S, et al: Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. Mod Pathol 2017; 30: 486–498.
19.
Jongmans MC, Kuiper RP, Carmichael CL, et al: Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia 2010; 24: 242–246.
20.
Noris P, Perrotta S, Seri M, et al: Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 2011; 117: 6673–6680.
21.
Marquez R, Hantel A, Lorenz R, et al: A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma 2014; 55: 2945–2946.
22.
Perez Botero J, Oliveira JL, Chen D, et al: ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J 2015; 5:e315.
23.
Moriyama T, Metzger ML, Wu G, et al: Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol 2015; 16: 1659–1666.
24.
Noetzli L, Lo RW, Lee-Sherick AB, et al: Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet 2015; 47: 535–538.
25.
Topka S, Vijai J, Walsh MF, et al: Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet 2015; 11:e1005262.
26.
Zhang MY, Churpek JE, Keel SB, et al: Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet 2015; 47: 180–185.
27.
Melazzini F, Palombo F, Balduini A, et al: Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica 2016; 101: 1333–1342.
28.
Vinh DC, Patel SY, Uzel G, et al: Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519–1529.
29.
Hsu AP, Sampaio EP, Khan J, et al: Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118: 2653–2655.
30.
Dickinson RE, Griffin H, Bigley V, et al: Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118: 2656–2658.
31.
Hahn CN, Chong CE, Carmichael CL, et al: Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43: 1012–1017.
32.
Ostergaard P, Simpson MA, Connell FC, et al: Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929–931.
33.
Pasquet M, Bellanne-Chantelot C, Tavitian S, et al: High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMAC syndrome, myelodysplasia, and acute myeloid leukemia. Blood 2013; 121: 822–829.
34.
Dickinson RE, Milne P, Jardine L, et al: The evolution of cellular deficiency in GATA2 mutation. Blood 2014; 123: 863–874.
35.
Spinner MA, Sanchez LA, Hsu AP, et al: GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123: 809–821.
36.
Ganapathi KA, Townsley DM, Hsu AP, et al: GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood 2015; 125: 56–70.
37.
Hyde RK, Liu PP: GATA2 mutations lead to MDS and AML. Nat Genet 2011; 43: 926–927.
38.
West RR, Hsu AP, Holland SM, Cuellar-Rodriguez J, Hickstein DD: Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica 2014; 99: 276–281.
39.
Calvo KR, Vinh DC, Maric I, et al: Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica 2011; 96: 1221–1225.
40.
Wlodarski MW, Hirabayashi S, Pastor V, et al: Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016; 127: 1387–1397; quiz 518.
41.
Bluteau O, Sebert M, Leblanc T, et al: A landscape of germline mutations in a cohort of inherited bone marrow failure patients. Blood 2018; 131: 717–732.
42.
Schwartz JR, Ma J, Lamprecht T, et al: The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun 2017; 8: 1557.
43.
Narumi S, Amano N, Ishii T, et al: SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 2016; 48: 792–797.
44.
Buonocore F, Kuhnen P, Suntharalingham JP, et al: Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans. J Clin Invest 2017; 127: 1700–1713.
45.
Tesi B, Davidsson J, Voss M, et al: Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood 2017; 129: 2266–2279.
46.
Schwartz JR, Wang S, Ma J, et al: Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome. Leukemia 2017; 31: 1827–1830.
47.
Balduini CL, Savoia A: Genetics of familial forms of thrombocytopenia. Hum Genet 2012; 131: 1821–1832.
48.
Balduini CL, Melazzini F, Pecci A: Inherited thrombocytopenias – recent advances in clinical and molecular aspects. Platelets 2017; 28: 3–13.
49.
Drachman JG: Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103: 390–398.
50.
Zaninetti C, Santini V, Tiniakou M, Barozzi S, Savoia A, Pecci A: Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. J Thromb Haemost 2017; 15: 2388–2392.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
